<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">IJCM</journal-id><journal-title-group><journal-title>International Journal of Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2158-284X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ijcm.2018.91002</article-id><article-id pub-id-type="publisher-id">IJCM-81665</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Highly Selective Photodynamic Therapy with a Short Drug-Light Interval Using a Cytotoxic Photosensitizer Porphyrus Envelope for Drug-Resistant Prostate Cancer Cells
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Youngsoon</surname><given-names>Hong</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mizuho</surname><given-names>Inai</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Norihiro</surname><given-names>Honda</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hisanao</surname><given-names>Hazama</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Manjusha</surname><given-names>A. Joshi</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hiroyuki</surname><given-names>Nakamura</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Tomoyuki</surname><given-names>Nishikawa</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yasufumi</surname><given-names>Kaneda</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kunio</surname><given-names>Awazu</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Graduate School of Engineering, Osaka University, Osaka, Japan</addr-line></aff><aff id="aff3"><addr-line>Institute of Academic Initiatives, Osaka University, Osaka, Japan</addr-line></aff><aff id="aff2"><addr-line>Graduate School of Frontier Biosciences, Osaka University, Osaka, Japan</addr-line></aff><aff id="aff4"><addr-line>Institute of Innovative Research, Tokyo Institute of Technology, Kanagawa, Japan</addr-line></aff><aff id="aff5"><addr-line>Graduate School of Medicine, Osaka University, Osaka, Japan</addr-line></aff><aff id="aff6"><addr-line>Global Centre for Medical Engineering and Informatics, Osaka University, Osaka, Japan</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>hong-y@mb.see.eng.osaka-u.ac.jp(YH)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>01</month><year>2018</year></pub-date><volume>09</volume><issue>01</issue><fpage>8</fpage><lpage>22</lpage><history><date date-type="received"><day>29,</day>	<month>November</month>	<year>2017</year></date><date date-type="rev-recd"><day>8,</day>	<month>January</month>	<year>2018</year>	</date><date date-type="accepted"><day>11,</day>	<month>January</month>	<year>2018</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Background: Photodynamic therapy (PDT) is a less invasive cancer treatment using photochemical reactions induced by light irradiation to a photosensitizer (PS). Highly selective PDT with fast accumulation of the PS in target site might be a promising treatment option for drug-resistant prostate cancer facing high incidence rate of elderly men who have no effective treatment options and require a minimally invasive treatment. Hemagglutinating virus of Japan envelope (HVJ-E) allows selective and fast drug delivery to the drug-resistant prostate cancer cells via rapid cell membrane fusion. PS named porphyrus envelope (PE) has been developed by insertion of lipidated protoporphyrin IX (PpIX lipid) into HVJ-E. In this study, we investigated the optimal conditions for PE preparation and laser irradiation for highly selective PDT using PE with a short drug-light interval. 
  Materials and Methods: Human hormon refractory prostate cancer cell line PC-3 and human normal prostate epithelial cell line PNT2 were cultured. PpIX lipid uptake and cytotoxicity of PDT in the cells incubated with PE for 10 min were evaluated by measuring fluorescence intensity and by using a cell counting reagent 24 h after PDT, respectively. 
  Results: PpIX lipid uptake and cytotoxicity of PDT were increased with PpIX lipid concentration. Cytotoxicity of PDT using PE was more than 9 times as strong as that with PpIX lipid and PpIX induced by 5-aminolevulinic acid. Much stronger cytotoxicity was induced in PC-3 cells than PNT2 cells with the ratio of cell death rate for cancer to normal cells up to 4.64 &#177; 0.09. Conclusions: Fast PS delivery with HVJ-E allows highly selective PDT with a short drug-light interval. Therefore, PDT using PE has a potential to shorten treatment period and reduce side effects of PDT.
 
</p></abstract><kwd-group><kwd>Photodynamic Therapy</kwd><kwd> Hemagglutinating Virus of Japan Envelope</kwd><kwd> Drug Delivery System</kwd><kwd> Short Drug-Light Interval</kwd><kwd> Drug-Resistant Prostate Cancer</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Prostate cancer is becoming the most common cancer due to the aging population [<xref ref-type="bibr" rid="scirp.81665-ref1">1</xref>] . Hormone therapy has been considered as an effective treatment since prostate cancer grows with androgen. However, cancer cells often become resistant to the therapy [<xref ref-type="bibr" rid="scirp.81665-ref2">2</xref>] , and disease progress requires that patients undergo chemotherapy whose response rate is not high enough to radically cure such drug- resistant prostate cancer [<xref ref-type="bibr" rid="scirp.81665-ref3">3</xref>] .</p><p>Photodynamic therapy (PDT) is a cancer treatment using photochemical reactions induced by light irradiation to a photosensitizer (PS). The PS is excited by a specific wavelength of light and reacts with surrounding substrates or oxygen to produce reactive oxygen species (ROS) that damages tissues where the PS is localized [<xref ref-type="bibr" rid="scirp.81665-ref4">4</xref>] . Unlike an anticancer drug, the PS alone exhibits no severe cell toxicity [<xref ref-type="bibr" rid="scirp.81665-ref5">5</xref>] , and low power light irradiation allows patients to obtain therapeutic efficacy after repeated treatment [<xref ref-type="bibr" rid="scirp.81665-ref6">6</xref>] . These characteristics of drugs and laser irradiation suggest that PDT is a potential treatment for drug-resistant prostate cancer [<xref ref-type="bibr" rid="scirp.81665-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.81665-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.81665-ref9">9</xref>] . Selectivity in therapeutic efficacy of conventional PDT is mainly related to the selective accumulation of the PS in tumor tissue or neovasculature. In reality, however, the PS itself has poor selectivity, leading to the long interval lasting from administration of the PS to light irradiation for maximization of the gap of PS concentration in between tumor and normal tissue. This interval is known as “drug-light interval” and patients need to stay out sun and room light for 3 - 48 h [<xref ref-type="bibr" rid="scirp.81665-ref10">10</xref>] . Poor selectivity of PSs is also associated with side effects such as normal tissue damage and skin photosensitivity after treatment. Especially, photosensitivity results in prolong light shielding period for 1 - 4 weeks that increases treatment cost and makes patients feel uncomfortable about the therapy [<xref ref-type="bibr" rid="scirp.81665-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.81665-ref12">12</xref>] .</p><p>To overcome these problems in clinical, a number of site-specific delivery of the PS has been received much attention. Replication-defective hemagglutinating virus of Japan (HVJ) envelope (HVJ-E) particle is considered to be a safe and effective carrier of DNA, proteins and drugs [<xref ref-type="bibr" rid="scirp.81665-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.81665-ref14">14</xref>] to a target cell. HVJ-E introduces those contents in cells thorough membrane fusion process via two types of viral proteins on its surface called hemagglutinin-neuraminidase (HN) and fusion (F) protein [<xref ref-type="bibr" rid="scirp.81665-ref15">15</xref>] . HN protein binds to its receptor gangliosides on host cell membrane, and then F protein-mediated membrane fusion occurs [<xref ref-type="bibr" rid="scirp.81665-ref16">16</xref>] . HVJ-E has two characteristics suitable as a carrier of the PS to drug-resistant prostate cancer cells. First, receptors of HN protein are more expressed in human drug-resistant prostate cancer cell lines PC-3 and DU145 compared with the normal prostate epithelial cell line PNT2 [<xref ref-type="bibr" rid="scirp.81665-ref17">17</xref>] . This cancer-specific expression of receptors enables HVJ-E to selectively deliver the PS to such prostate cancer cells. Second, membrane fusion takes place immediately after the adsorption of HVJ-E to the cells within a few minutes [<xref ref-type="bibr" rid="scirp.81665-ref18">18</xref>] , and localization of the PS in the cell membrane significantly enhances therapeutic efficacy of PDT by inducing substantial membrane disruption upon laser irradiation even at a low PS concentration [<xref ref-type="bibr" rid="scirp.81665-ref19">19</xref>] . Taken together, rapid membrane fusion has a possibility to induce strong cytotoxicity in cancer cells at a short drug-light interval.</p><p>These characteristics of HVJ-E suggest that delivery of the PS by HVJ-E induces selective cytotoxicity of PDT in drug-resistant prostate cancer at a short drug-light interval. We have previously developed a PS named porphyrus envelope (PE) by insertion of lipidated protoporphyrin IX (PpIX lipid) into HVJ-E [<xref ref-type="bibr" rid="scirp.81665-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.81665-ref21">21</xref>] . Previous study showed that PE undergoes membrane fusion with PC-3 cells by 10 min incubation [<xref ref-type="bibr" rid="scirp.81665-ref22">22</xref>] and PpIX lipid localizes in the cell membrane [<xref ref-type="bibr" rid="scirp.81665-ref23">23</xref>] . However, the optimal conditions for PE preparation and light irradiation for PDT with a short drug-light interval have not been clarified and selectivity in PDT using PE remains unclear. In this study, we examined uptake kinetics of PE-mediated PpIX lipid and cytotoxicity of PDT in both PC-3 and PNT2 cells with the 10 min drug-light interval in order to determine the optimal concentration of PpIX lipid loaded in PE and light irradiation energy density for highly selective PDT against drug-resistant prostate cancer cells.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Cell Culture</title><p>Hormone refractory human prostate cancer cell line PC-3 and human normal prostate epithelial cell line PNT2 were purchased from the American Type Culture Collection (USA), respectively. The cell lines were cultured in Dulbecco’s modified Eagle’s medium (D6046, Sigma-Aldrich, USA) with fetal bovine serum (S1820, Biowest, France) and 100 units/mL penicillin-streptomycin (P4458, Sigma-Aldrich). The cells were incubated at 37˚C humidified atmosphere containing 5% CO<sub>2</sub>. PC-3 and PNT2 cells were reseeded after reaching confluence of 80% and 70%, respectively.</p></sec><sec id="s2_2"><title>2.2. Photosensitizers</title><p>5-aminolevulinic acid hydrochloride (5-ALA, A7793, Sigma-Aldrich) was diluted in the culture medium to a concentration of 1 mM. An aqueous solution of 5 mMPpIX lipid was prepared by synthesizing two lithium groups and two lipid chains to PpIX in order to enhance its water-solubility and be inserted into HVJ-E as previously reported [<xref ref-type="bibr" rid="scirp.81665-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.81665-ref21">21</xref>] . PpIX lipid solution was diluted in the culture medium to a concentration of a 28.5 &#181;M. HVJ-E was prepared by irradiation of ultraviolet light to HVJ at an energy density of 99 mJ/cm<sup>2</sup> in order to make its RNA genome fragmented and inactivate its replication activity. HVJ-E was diluted in 1 mL of Dulbecco’s phosphate buffered saline (D-PBS, D8537, Sigma-Aldrich) to a titer of 2500 hemagglutination units (HAU) and purified by centrifugation (20,000 &#215; g, 4˚C, 10 min). The pellet of HVJ-E was suspended in 1 mL of PpIX lipid solution which was diluted in D-PBS to the concentration range of 0 - 24.1 &#181;M. The suspension was heated to 37˚C for 5 min, followed by insertion of PpIX lipid into HVJ-E by centrifugation (20,000 &#215; g, 4˚C, 10 min) with ratios of the amount of PpIX lipid to titer of HVJ-E for 0 - 9.65 pmol/HAU. After centrifugation, PE was prepared by suspending the pellet in 833 &#181;L of the culture medium. In all the experiments, the culture medium and PSs were administrated to the cells at a dose of 50 &#181;L.</p></sec><sec id="s2_3"><title>2.3. Light Source and Optical Setup</title><p>A laser diode (VLM 500, Sumitomo Electric Industries, Japan) emitting continuous wave light with a wavelength of 405 nm was used as a light source. The wavelength corresponds to the highest absorption peak of PE [<xref ref-type="bibr" rid="scirp.81665-ref21">21</xref>] and the effects of absorption and scattering of the light at wavelengths of around 400 nm are hardly observed in vitro experiment which does not use biological tissue but only cultured cells. The optical setup for PDT experiment is shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>. Laser light guided by an optical fiber (FT600EMT, Thorlabs, USA) was collimated to a diameter of 6.6 mm using an aperture and was irradiated to a clear bottom of a 96-well cell culture plate with a black wall (Falcon&#174; 353219, BD, USA) where the cells were maintained at the temperature of 37˚C using a plate warmer (KM-1, Kitazato Science, Japan). The distance between the tip of the fiber and a bottom of the cell culture plate was vertically adjusted to 90 mm. Each well of the plate was irradiated with a laser light at an average power density of 100 mW/cm<sup>2</sup>. The position of the cell culture plate was automatically controlled by a two-axis motorized linear stage (SGSP26-150(XY), Sigmakoki, Japan) and changed when each irradiation time had finished.</p></sec><sec id="s2_4"><title>2.4. Dependence of PS Uptake and PDT Efficacy in PC-3 Cells on PpIX Lipid Concentration</title><sec id="s2_4_1"><title>2.4.1. Evaluation of Cellular PS Uptake</title><p>PC-3 cells were seeded into a 96-well cell culture plate (Falcon&#174; 353219, BD) at a concentration of 5.0 &#215; 10<sup>3</sup> cells/100 &#181;L in each well and incubated at 37˚C containing 5% CO<sub>2</sub> for 24 h. Subsequently, the cells were incubated with the culture medium, or PE suspension in the PpIX lipid concentration range of 0.6 - 9.65 pmol/HAU for 10 min, and were washed with 100 &#181;L of D-PBS. After washing, 100 &#181;L of 0.1% sodium dodecyl sulfate (SDS, 31606-75, NacalaiTesque, Japan) solution in D-PBS was added to the cells in order to dissolve cellular lipids and proteins, followed by incubation of cells for 10 min. Fluorescence intensity of</p><p>cell lysate was measured by a fluorescence microplate reader (SpectraMAX Gemini, Molecular Devices, USA) at excitation and fluorescence wavelengths of 401 nm and 625 nm, respectively.</p></sec><sec id="s2_4_2"><title>2.4.2. PDT Procedure</title><p>PC-3 cells were incubated as described above. PpIX lipid loaded in PE was prepared to the concentration range of 1.75 - 9.5 pmol/HAU. Subsequently, the cells were washed with 100 &#181;L of D-PBS and a 100 &#181;L of the fresh culture medium was added to the cells. Immediately after addition of the medium, cells were irradiated using a laser light for 60 s at an energy density of 6 J/cm<sup>2</sup>.</p></sec><sec id="s2_4_3"><title>2.4.3. Comparison of PDT Efficacy of PE with That of PpIX Lipid Alone and 5-ALA-Induced PpIX</title><p>PC-3 cells were incubated as described above, and incubated with the culture medium, PpIX lipid, 5-ALA solution, or PE suspension with 9.5 pmol/HAU PpIX lipid for 10 min, 30 min, 1 h, or 2 h. Subsequently, the cells were washed with D-PBS, and the fresh culture medium was added. Then laser light was irradiated as described above.</p></sec></sec><sec id="s2_5"><title>2.5. Evaluation of Selectivity</title><sec id="s2_5_1"><title>2.5.1. Evaluation of Cellular PS Uptake</title><p>PC-3 and PNT2 cells were seeded into a 96-well cell culture plate (Falcon&#174; 353219, BD) at a concentration of 5.0 &#215; 10<sup>3</sup> cells/100 &#181;L in each well and incubated at 37˚C containing 5% CO<sub>2</sub> for 24 h. Subsequently, cells were incubated with the culture medium or PE in the PpIX lipid concentration range of 1.19 - 9.5 pmol/HAU for 10 min, 30 min, or 1 h. After incubation, the cells underwent washing with D-PBS, adding of 0.1% SDS solution in D-PBS, and measurement of fluorescence intensity of its lysate, as described in 2.4.1.</p></sec><sec id="s2_5_2"><title>2.5.2. PDT Procedure</title><p>PC-3 and PNT2 cells were incubated as described above but with culture medium or PE for only 10 min, respectively. Subsequently, the cells underwent washing with D-PBS and adding of the fresh culture medium as described in 2.4.2. Immediately after addition of the medium, cells were irradiated using a laser light for 0 - 180 s in energy density range of 0 - 18 J/cm<sup>2</sup>.</p></sec></sec><sec id="s2_6"><title>2.6. Cell Survival Assay</title><p>Cells irradiated with a laser light were incubated at 37˚C containing 5% CO<sub>2</sub> for 24 h, and the culture medium in each well was replaced with the mixture of 100 &#181;L of the fresh culture medium and 10 &#181;L of a cell counting reagent (07553-44, NacalaiTesque, Japan) containing water-soluble tetrazolium salt (WST-8). Cells were further incubated for 1 h, and the optical density (OD) of the culture medium containing formazan dye produced upon reduction of WST-8 by dehydrogenases in a living cell was measured at a wavelength of 450 nm using an absorbance microplate reader (VersaMAX, Molecular Devices). Cell survival rate was defined as the ratio of OD of the cells exposed to the PS and laser light, to that of the cells which were exposed to laser light only.</p></sec><sec id="s2_7"><title>2.7. Statistical Analysis</title><p>Statistical analysis was conducted using a two-tailed unpaired Student’s t-test for detecting the significant difference between two samples and probability values of P &lt; 0.05 were considered to indicate statistical significance.</p></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. PpIX Lipid Uptake and Cytotoxicity of PDT Increased with PpIX Lipid Concentration in PE</title><p>To determine the PpIX lipid concentration required for PDT using PE with the 10 min drug-light interval against PC-3 cells, the amount of PpIX lipid and cytotoxicity of PDT were assessed using PE with different PpIX lipid concentrations. Concentration-dependent PpIX lipid uptake was observed at PpIX lipid concentration higher than 1.21 pmol/HAU (<xref ref-type="fig" rid="fig2">Figure 2</xref>(a)). The cytotoxicity of PDT increased with the concentration of PpIX lipid loaded in PE, and survival rate of PC-3 cells decreased to 10% at a concentration of 9.5 pmol/HAU (<xref ref-type="fig" rid="fig2">Figure 2</xref>(b)). These results suggested that increase of PpIX lipid concentration in PE</p><p>can induce strong photo-cytotoxic effect of PDT in PC-3 cells at the 10 min drug-light interval.</p></sec><sec id="s3_2"><title>3.2. PDT Using PE Induced Much Stronger Photo-Cytotoxicity than That of Other PpIX-Mediated PDT</title><p>To confirm whether PDT using PE could induce stronger photo-cytotoxicity at the 10 min drug-light interval than that of other PpIX-mediated PDT, PC-3 cells were incubated with the culture medium, PE, PpIX lipid alone, or 5-ALA which is metabolized into PpIX in a cellular mitochondria. At the 10 min drug-light interval, survival rates of PC-3 cells incubated with PpIX lipid alone and 5-ALA were 100% and 90%, respectively, and the rates decreased with the increase of drug-light interval, while survival rate of the cells incubated with PE was lower than 10%, and time-dependent decrease in cell survival rate was hardly observed in the drug-light interval of between 10 min and 2 h (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p></sec><sec id="s3_3"><title>3.3. PE Allowed Selective Delivery of PpIX Lipid Even at a Short Incubation Period</title><p>To examine the selectivity for uptake kinetics of PpIX lipid, the amounts of PpIX lipid in PC-3 and PNT2 cells were assessed under different PpIX lipid concentrations in PE and incubation periods. Significant increases in fluorescence intensities were observed in PC-3 cells in all PpIX lipid concentrations and incubation periods (<xref ref-type="fig" rid="fig4">Figure 4</xref>). The tumor to normal cell ratio (T/N ratio) of fluorescence intensity at an incubation period of 10 min was 1.19 &#177; 0.07 - 2.10 &#177; 0.20, and time-dependent increase in T/N ratio was hardly, or not observed in each PpIX lipid concentration. These results suggested that cytotoxicity of PDT using PE can be selectively induced in cancer cells with a short drug-light interval.</p></sec><sec id="s3_4"><title>3.4. PE-Mediated PDT Induces Highly Selective Cytotoxicity with a Short Drug-Light Interval</title><p>To determine doses of PpIX lipid and laser light which are required for highly selective PDT using PE with a short drug-light interval, the cytotoxicity of PDT in PC-3 and PNT2 cells were assessed using PE with different PpIX lipid concentrations and light irradiation energy densities at the 10 min drug-light interval. When the cells were not exposed to laser light, or incubated with PE at a PpIX lipid concentration of 1.19 pmol/HAU, survival rates of PC-3 and PNT2 cells were 40% - 50% and 70% - 80%, respectively (<xref ref-type="fig" rid="fig5">Figure 5</xref>). Survival rates of PC-3 cells decreased with the increase of irradiation energy density at the PpIX lipid concentration higher than 2.38 pmol/HAU, while no energy density dependent decrease in survival rate of PNT2 cells was observed at a PpIX lipid concentration of 2.38 pmol/HAU. Laser irradiation at energy densities of 12 J/cm<sup>2</sup> and 6 J/cm<sup>2</sup> induced photo-cytotoxic effects in PNT2 cells at PpIX lipid concentrations of 4.75 pmol/HAU and 9.5 pmol/HAU, respectively. The decreases in survival rates of PNT2 cells incubated with PE at PpIX lipid concentrations of 4.75 pmol/HAU and 9.5 pmol/HAU were also observed by laser irradiation to the cells in the energy density ranges of 8 - 12 J/cm<sup>2</sup> and 1 - 4 J/cm<sup>2</sup>, respectively (data not shown). Ultimately, laser irradiation at energy densities of 18 J/cm<sup>2</sup> and 6 J/cm<sup>2</sup> with PpIX lipid concentrations of 2.38 pmol/HAU and 4.75 pmol/HAU, respectively, obtained the highest T/N ratios of cell death in PDT using PE at the 10 min drug-light interval. The ratios in each PDT conditions were estimated to be 4.64 &#177; 0.09 and 4.54 &#177; 0.01, respectively (<xref ref-type="table" rid="table1">Table 1</xref>).</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>As shown in <xref ref-type="fig" rid="fig4">Figure 4</xref>, PE showed the selective uptake in all PpIX lipid concentrations and incubation periods, and distinct time-dependent increases in selectivity were hardly observed. We consider that rapid and cancer-selective PS delivery by HVJ-E allowed selective accumulation of the PS even at a short incubation period [<xref ref-type="bibr" rid="scirp.81665-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.81665-ref25">25</xref>] . Based on this, we performed PDT using PE with high concentration of PpIX lipid (9.5 pmol/HAU) at the 10 min drug-light interval and revealed that PE induced much stronger cytotoxicity in PC-3 cells than PpIX lipid alone and 5-ALA (<xref ref-type="fig" rid="fig3">Figure 3</xref>) probably due to the rapid delivery of PpIX lipid into the cell membrane and effective induction of cell death [<xref ref-type="bibr" rid="scirp.81665-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.81665-ref21">21</xref>] [<xref ref-type="bibr" rid="scirp.81665-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.81665-ref23">23</xref>] .</p><p>In this study, we also evaluated the selectivity of cell death induced by PDT using PE with the 10 min drug-light interval. As shown in <xref ref-type="table" rid="table1">Table 1</xref>, T/N ratio of cell death in PDT was higher than that of PE uptake. It is known that selective apoptosis in PC-3 cells but not in PNT2 cells is induced via recognition of fragmented HVJ-E’s RNA genome by intracellular retinoic acid-inducible gene-I whose signaling pathway selectively activates apoptosis-inducing ligands in PC-3 cells [<xref ref-type="bibr" rid="scirp.81665-ref26">26</xref>] . In this study, survival rates of PC-3 cells were lower than those of PNT2 cells by 30% - 40% in all PpIX lipid concentrations without laser irradiation. Previous study reported that PE also selectively induced cytotoxicity in</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> T/N ratio of cell death in PDT using PE with the 10 min drug-light interval under different PpIX lipid concentrations and irradiation energy densities. The ratio was calculated by division of the cell death rate for PC-3 cells to PNT2 cells based using the cell survival rates shown in <xref ref-type="fig" rid="fig5">Figure 5</xref>. Laser irradiation at energy densities of 18 J/cm<sup>2</sup> and 6 J/cm<sup>2</sup> with PpIX lipid concentrations of 2.38 pmol/HAU and 4.75 pmol/HAU, respectively, showed the highest T/N ratios of cell death of 4.64 &#177; 0.09 and 4.54 &#177; 0.01, respectively</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Energy density [J/cm<sup>2</sup>]</th><th align="center" valign="middle"  colspan="4"  >PpIX lipid concentration [pmol/HAU]</th></tr></thead><tr><td align="center" valign="middle" >1.19<sub> </sub></td><td align="center" valign="middle" >2.38</td><td align="center" valign="middle" >4.75</td><td align="center" valign="middle" >9.5</td></tr><tr><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1.72 &#177; 0.04</td><td align="center" valign="middle" >1.87 &#177; 0.03</td><td align="center" valign="middle" >1.69 &#177; 0.06</td><td align="center" valign="middle" >1.94 &#177; 0.05</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >1.48 &#177; 0.04</td><td align="center" valign="middle" >1.91 &#177; 0.03</td><td align="center" valign="middle" >4.54 &#177; 0.01</td><td align="center" valign="middle" >4.31 &#177; 0.01</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >1.80 &#177; 0.03</td><td align="center" valign="middle" >3.91 &#177; 0.02</td><td align="center" valign="middle" >1.82 &#177; 0.00</td><td align="center" valign="middle" >1.50 &#177; 0.00</td></tr><tr><td align="center" valign="middle" >18</td><td align="center" valign="middle" >2.00 &#177; 0.04</td><td align="center" valign="middle" >4.64 &#177; 0.09</td><td align="center" valign="middle" >0.69 &#177; 0.03</td><td align="center" valign="middle" >2.28 &#177; 0.03</td></tr></tbody></table></table-wrap><p>PC-3 cells but not in PNT2 cells, and the cytotoxicity was maintained even after PE had been subjected to laser light at an energy density of 6 J/cm<sup>2</sup> with the same light source and power density, as described in this study [<xref ref-type="bibr" rid="scirp.81665-ref23">23</xref>] . Other study reported that there was threshold of cellular PpIX amount for cell killing and T/N ratio of cellular PpIX uptake did not strictly correspond to that of cell death [<xref ref-type="bibr" rid="scirp.81665-ref27">27</xref>] . In this study, when PNT2 cells were incubated with PE at PpIX lipid concentrations of 2.38 pmol/HAU and 4.75 pmol/HAU and were irradiated with laser light at energy densities of 0 - 18 J/cm<sup>2</sup> and 0 - 6 J/cm<sup>2</sup>, respectively, cancer-selective decreases in cell survival rates were observed with the increase of laser irradiation energy density. This result suggested that the amount of cellular PpIX lipid loaded in PE at those concentrations did not show the threshold amount in PNT2 cells for inducing cell death. Taken together, higher selectivity of cell death than that of PpIX lipid uptake was possibly owed to HVJ-E’s derived cancer-selective cytotoxicity and low PpIX lipid amount in PNT2 cells which did not show threshold amount for cell killing.</p><p>Finally, the highest T/N ratios of cell death were observed in following conditions:</p><p>1) PpIX lipid concentration of 2.38 pmol/HAU and laser energy density of 18 J/cm<sup>2</sup>,</p><p>2) PpIX lipid concentration of 4.75 pmol/HAU and laser energy density of 6 J/cm<sup>2</sup>.</p><p>In clinical, PSs are not always distributed homogenously in tissue. This indicates that long laser irradiation period possibly gives damages to normal cells where high concentration of PSs accumulates. In this study, PE with a PpIX lipid concentration of 4.75 pmol/HAU induced substantial decrease in survival rate of PNT2 cells at laser irradiation energy densities of 12 J/cm<sup>2</sup> and 18 J/cm<sup>2</sup>, while no energy density-dependent decrease in the cell survival rate was observed in PE at a PpIX lipid concentration of 2.38 pmol/HAU. These results suggest that PDT using PE should be conducted with low PpIX lipid concentration of PE and long irradiation period, as shown in condition (1), in order not to generate acute cytotoxicity to normal cells since high incidence rate of drug-resistant prostate cancer is observed in elderly people over 65 years [<xref ref-type="bibr" rid="scirp.81665-ref1">1</xref>] and patients often need minimally invasive cancer treatments.</p><p>Much stronger cytotoxicity was induced in PC-3 cells than PNT2 cells with the T/N ratio of 4.64 &#177; 0.09 under condition (1). There have been some reports that have shown the photo-cytotoxicity in between PC-3 cells and normal prostate cell lines, however, the lower T/N ratios of cell death were observed by as much as 1.5 - 2 in other PSs [<xref ref-type="bibr" rid="scirp.81665-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.81665-ref29">29</xref>] . This suggested that PE has the possibility to allow highly selective treatment for drug-resistant prostate cancer with a much shorter drug-light interval.</p><p>Previous studies have shown the safety and efficacy of intratumoral administration of HVJ-E to drug-resistant prostate cancer tissue in the phase of pre-clinical and clinical trials [<xref ref-type="bibr" rid="scirp.81665-ref30">30</xref>] [<xref ref-type="bibr" rid="scirp.81665-ref31">31</xref>] . It has been reported that intratumoral administration of the PS induces high level of PS concentration in tumor tissue at a shorter drug-light interval with an advantage of the much higher tumor to normal skin ratio for accumulation of the PS [<xref ref-type="bibr" rid="scirp.81665-ref32">32</xref>] [<xref ref-type="bibr" rid="scirp.81665-ref33">33</xref>] . Furthermore, tumor-specific PS delivery is known to be a promising strategy to further improve the accumulation efficacy and retention of the PS which is directly administrated into tumor tissue [<xref ref-type="bibr" rid="scirp.81665-ref34">34</xref>] [<xref ref-type="bibr" rid="scirp.81665-ref35">35</xref>] . Therefore, the possibility of intratumoral administration of PE in vivo trials probably provides higher selectivity in PDT with a short drug-light interval than in vitro experiments, as reported in this study.</p></sec><sec id="s5"><title>5. Conclusion</title><p>In this study, we focused on the fast delivery of the PS by HVJ-E and have demonstrated highly selective cytotoxicity of in vitro PDT using PE against drug-resistant prostate cancer cells with a short drug-light interval. This result suggests that PE-mediated PDT can shorten drug-light interval and reduce PDT-mediated side effects, and gives the possibility to apply PDT to a novel treatment modality for drug-resistant prostate cancer in clinical.</p></sec><sec id="s6"><title>Acknowledgements</title><p>We are deeply grateful to Erica Miyake Lin for technical assistance with the experiments. This work was supported by JSPS KAKENHI Grant Number JP15K16322 and JGC-S SCHOLARSHIP FOUNDATION Grant Number 1605.</p></sec><sec id="s7"><title>Cite this paper</title><p>Hong, Y., Inai, M., Honda, N., Hazama, H., Joshi, M.A., Nakamura, H., Nishikawa, T., Kaneda, Y. and Awazu, K. (2018) Highly Selective Photodynamic Therapy with a Short Drug-Light Interval Using a Cytotoxic Photosensitizer Porphyrus Envelope for Drug-Resistant Prostate Cancer Cells. International Journal of Clinical Medicine, 9, 8-22. https://doi.org/10.4236/ijcm.2018.91002</p></sec></body><back><ref-list><title>References</title><ref id="scirp.81665-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Quon, H., Loblaw, A. and Nam, R. (2011) Dramatic Increase in Prostate Cancer Cases by 2021. BJU International, 108, 1734-1738.  https://doi.org/10.1111/j.1464-410X.2011.10197.x</mixed-citation></ref><ref id="scirp.81665-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Fuessel, S., Meye, A., Schmitz, M., Zastrow, S., Linné, C., Richter, K., L&amp;ouml;bel, B., Hakenberg, O.W., Hoelig, K., Rieber, E.P. and Wirth, M.P. (2006) Vaccination of Hormone-Refractory Prostate Cancer Patients with Peptide Cocktail-Loaded Dendritic Cells: Results of a Phase I Clinical Trial. The Prostate, 66, 811-821. https://doi.org/10.1002/pros.20404</mixed-citation></ref><ref id="scirp.81665-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bhandari, M.S., Petrylak, D.P. and Hussain, M. (2005) Clinical Trials in Metastatic Prostate Cancer—Has There Been Real Progress in the Past Decade? European Journal of Cancer, 41, 941-953. https://doi.org/10.1016/j.ejca.2005.02.008</mixed-citation></ref><ref id="scirp.81665-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Baier, J., Maier, M., Engl, R., Landthaler, M. and B&amp;auml;umler, W. (2005) Time-Resolved Investigations of Singlet Oxygen Luminescence in Water, in Phosphatidylcholine, and in Aqueous Suspensions of Phosphatidylcholine or HT29 Cells. The Journal of Physical Chemistry B, 109, 3041-3046. https://doi.org/10.1021/jp0455531</mixed-citation></ref><ref id="scirp.81665-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ethirajan, M., Chen, Y., Joshi, P. and Pandey, R.K. (2011) The Role of Porphyrin Chemistry in Tumor Imaging and Photodynamic Therapy. Chemical Society Reviews, 40, 340-362. https://doi.org/10.1039/B915149B</mixed-citation></ref><ref id="scirp.81665-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Usuda, J., Kato, H., Okunaka, T., Furukawa, K., Tsutsui, H., Yamada, K., Suga, Y., Honda, H., Nagatsuka, Y., Ohira, T., Tsuboi, M. and Hirano, T. (2006) Photodynamic Therapy (PDT) for Lung Cancers. Journal of Thoracic Oncology, 1, 489-493. https://doi.org/10.1016/S1556-0864(15)31616-6</mixed-citation></ref><ref id="scirp.81665-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Trachtenberg, J., Bogaards, A., Weersink, R.A., Haider, M.A., Evans, A., McCluskey, S.A., Scherz, A., Gertner, M.R., Yue, C., Appu, S., Aprikian, A., Savard, J., Wilson, B.C. and Elhilali, M. (2007) Vascular Targeted Photodynamic Therapy with Palladium-Bacteriopheophorbide Photosensitizer for Recurrent Prostate Cancer Following Definitive Radiation Therapy: Assessment of Safety and Treatment Response. The Journal of Urology, 178, 1974-1979. https://doi.org/10.1016/j.juro.2007.07.036</mixed-citation></ref><ref id="scirp.81665-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Trachtenberg, J., Weersink, R.A., Davidson, S.R.H., Haider, M.A., Bogaards, A., Gertner, M.R., Evans, A., Scherz, A., Savard, J., Chin, J.L., Wilson, B.C. and Elhilali, M. (2008) Vascular-Targeted Photodynamic Therapy (Padoporfin, WST09) for Recurrent Prostate Cancer after Failure of External Beam Radiotherapy: A Study of Escalating Light Doses. BJU International, 102, 556-562. https://doi.org/10.1111/j.1464-410X.2008.07753.x</mixed-citation></ref><ref id="scirp.81665-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Xua, D.D., Lamb, H.M., Hoevenc, R., Xu, C.B., Leung, A.W.N. and Cho, W.C.S. (2013) Photodynamic Therapy Induced Cell Death of Hormone Insensitive Prostate Cancer PC-3 Cells with Autophagic Characteristics. Photodiagnosis and Photodynamic Therapy, 10, 278-287. https://doi.org/10.1016/j.pdpdt.2013.01.002</mixed-citation></ref><ref id="scirp.81665-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Allison, R.R., Downie, G.H., Cuenca, R., Hu, X.H., Childs, C.J. and Sibata, C.H. (2004) Photosensitizers in Clinical PDT. Photodiagnosis and Photodynamic Therapy, 1, 27-42. https://doi.org/10.1016/S1572-1000(04)00007-9</mixed-citation></ref><ref id="scirp.81665-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Goldman, M.P., Fitzpatrick, R.E., Ross, E.V., Kilmer, S.L. and Weiss, R.A. (2013) Lasers and Energy Devices for the Skin. CRC Press Llc., Florida. https://doi.org/10.3109/9781841849348</mixed-citation></ref><ref id="scirp.81665-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Jang, Y.H., Lee, D.J., Shin, J., Kang, H.Y., Lee, E.S. and Kim, Y.C. (2013) Photodynamic Therapy with Ablative Carbon Dioxide Fractional Laser in Treatment of Actinic Keratosis. Annals of Dermatology, 25, 417-422. https://doi.org/10.5021/ad.2013.25.4.417</mixed-citation></ref><ref id="scirp.81665-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Kaneda, Y., Yamamoto, S. and Nakajima, T. (2005) Development of HVJ Envelope Vector and Its Application to Gene Therapy. Advances in Genetics, 53, 307-332. https://doi.org/10.1016/S0065-2660(05)53012-8</mixed-citation></ref><ref id="scirp.81665-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Mima, H., Yamamoto, S., Ito, M., Tomoshige, R., Tabata, Y., Tamai, K. and Kaneda, Y. (2006) Targeted Chemotherapy against Intraperitoneally Disseminated Colon Carcinoma Using a Cationized Gelatin-Conjugated HVJ Envelope Vector. Molecular Cancer Therapeutics, 5, 1021-1028. https://doi.org/10.1158/1535-7163.MCT-05-0352</mixed-citation></ref><ref id="scirp.81665-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Kaneda, Y. (2012) Virosome: A Novel Vector to Enable Multi-Modal Strategies for Cancer Therapy. Advanced Drug Delivery Reviews, 64, 730-738. https://doi.org/10.1016/j.addr.2011.03.007</mixed-citation></ref><ref id="scirp.81665-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Tsurudome, M. (1999) Analyses of Paramyxovirus Glycoproteins Involved in the Induction of Cell Fusion. Uirusu, 49, 61-70. https://doi.org/10.2222/jsv.49.61</mixed-citation></ref><ref id="scirp.81665-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Kawaguchi, Y., Miyamoto, Y., Inoue, T. and Kaneda, Y. (2009) Efficient Eradication of Hormone-Resistant Human Prostate Cancers by Inactivated Sendai Virus Particle. International Journal of Cancer, 124, 2478-2487. https://doi.org/10.1002/ijc.24234</mixed-citation></ref><ref id="scirp.81665-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Kim, J. and Okada, Y. (1982) Morphological Changes in Ehrlich Ascites Tumor Cells during the Cell Fusion Reaction with HVJ (Sendai Virus): III. Morphological Characterization of HVJ Glycoproteins Integrated into the Plasma Membrane and Their Internalization by Coated Vesicles. Experimental Cell Research, 140, 127-136. https://doi.org/10.1016/0014-4827(82)90164-1</mixed-citation></ref><ref id="scirp.81665-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Kim, J., Santos, O.A. and Park, J.H. (2014) Selective Photosensitizer Delivery into Plasma Membrane for Effective Photodynamic Therapy. Journal of Controlled Release, 191, 98-104. https://doi.org/10.1016/j.jconrel.2014.05.049</mixed-citation></ref><ref id="scirp.81665-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Tachikawa, S., El-Zaria, M.E., Inomata, R., Sato, S. and Nakamura, H. (2014) Synthesis of Protoporphyrin-Lipids and Biological Evaluation of Micelles and Liposomes. Bioorganic &amp; Medicinal Chemistry, 22, 4745-4751. https://doi.org/10.1016/j.bmc.2014.07.003</mixed-citation></ref><ref id="scirp.81665-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Yamauchi, M., Honda, N., Hazama, H., Tachikawa, S., Nakamura, H., Kaneda, Y. and Awazu, K. (2014) A Novel Photodynamic Therapy for Drug-Resistant Prostate Cancer Cells using Porphyrus Envelope as a Novel Photosensitizer. Photodiagnosis and Photodynamic Therapy, 11, 48-54. https://doi.org/10.1016/j.pdpdt.2013.10.001</mixed-citation></ref><ref id="scirp.81665-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Inai, M., Ymauchi, M., Honda, N., Hazama, H., Tachikawa, S., Nakamura, H., Nishida, T., Yasuda, H., Kaneda, Y. and Awazu, K. (2015) Hemagglutinating Virus of Japan Envelope (HVJ-E) Allows Targeted and Efficient Delivery of Photosensitizer for Photodynamic Therapy against Advanced Prostate Cancer. Proceedings of Optics in the Life Sciences 2015, Vancouver, 12-15 April 2015, OM2D.3.</mixed-citation></ref><ref id="scirp.81665-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Inai, M., Honda, N., Hazama, H., Akter, S., Fuse, S., Nakamura, H., Nishikawa, T., Kaneda, Y. and Awazu, K. (2017) Photodynamic Therapy using a Cytotoxic Photosensitizer Porphyrus Envelope That Targets the Cell Membrane. Photodiagnosis and Photodynamic Therapy, 20, 238-245. https://doi.org/10.1016/j.pdpdt.2017.10.017</mixed-citation></ref><ref id="scirp.81665-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Andrejevic-Blant, S., Hadjur, C.H., BalIini, J.P., Wagnieres, G., Fontolliet, C.H., Van Den Bergh, H. and Monnier, P.H. (1997) Photodynamic Therapy of Early Squamous Cell Carcinoma with Tetra(M-Hydroxyphenyl)Chlorin: Optimal Drug-Light Interval. British Journal of Cancer, 76, 1021-1028. https://doi.org/10.1038/bjc.1997.502</mixed-citation></ref><ref id="scirp.81665-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">D’Hallewin, M.A., Kochetkov, D., Viry-Babel, Y., Leroux, A., Werkmeister, E., Dumas, D., Gr&amp;auml;fe, S., Zorin, V., Guillemin, F. and Bezdetnaya, L. (2008) Photodynamic Therapy with Intratumoral Administration of Lipid-Based mTHPC in a Model of Breast Cancer Recurrence. Lasers in Surgery and Medicine, 40, 543-549. https://doi.org/10.1002/lsm.20662</mixed-citation></ref><ref id="scirp.81665-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Matsushima-Miyagi, T., Hatano, K., Nomura, M., Li-Wen, L., Nishikawa, T., Saga, K., Shimbo, T. and Kaneda, Y. (2012) TRAIL and Noxa Are Selectively Upregulated in Prostate Cancer Cells Downstream of the RIG-I/MAVS Signaling Pathway by Nonreplicating Sendai Virus Particles. Clinical Cancer Research, 18, 6271-6283. https://doi.org/10.1158/1078-0432.CCR-12-1595</mixed-citation></ref><ref id="scirp.81665-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Iinuma, S., Farshi, S.S., Ortel, B. and Hasan, T. (1994) A Mechanistic Study of Cellular Photodestruction with 5-Aminolaevulinic Acid-Induced Porphyrin. British Journal of Cancer, 70, 21-28. https://doi.org/10.1038/bjc.1994.244</mixed-citation></ref><ref id="scirp.81665-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Colasanti, A., Kisslinger, A., Quarto, M. and Riccio, P. (2004) Combined Effects of Radiotherapy and Photodynamic Therapy on an in Vivo Human Prostate Model. ActaBiochimicaPolonica, 51, 1039-1046.</mixed-citation></ref><ref id="scirp.81665-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Lin, T.Y., Guo, W., Long, Q., Ma, A., Liu, Q., Zhang, H., Huang, Y., Chandrasekaran, S., Pan, C., Lam, K.S. and Li, Y. (2016) HSP90 Inhibitor Encapsulated Photo-Theranostic Nanoparticles for Synergistic Combination Cancer Therapy. Theranostics, 6, 1324-1335. https://doi.org/10.7150/thno.14882</mixed-citation></ref><ref id="scirp.81665-ref30"><label>30</label><mixed-citation publication-type="book" xlink:type="simple">Nakajima, T., Itai, T., Wada, H., Yamauchi, T., Kiyohara, E. and Kaneda, Y. (2013) A Novel Therapy for Melanoma and Prostate Cancer using a Non-Replicating Sendai Virus Particle (HVJ-E). In: Wei, M. and Good, D., Eds., Novel Gene Therapy Approaches, Intech, London, 157-181. https://doi.org/10.5772/55014</mixed-citation></ref><ref id="scirp.81665-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Fujita, K., Nakai, Y., Kawashima, A., Ujike, T., Nagahara, A., Nakajima, T., Inoue, T., Lee, C.M., Uemura, M., Miyagawa, Y., Kaneda, Y. and Nonomura, N. (2017) Phase I/II Clinical Trial to Assess Safety and Efficacy of Intratumoral and Subcutaneous Injection of HVJ-E in Castration-Resistant Prostate Cancer Patients. Cancer Gene Therapy, 24, 277-281. https://doi.org/10.1038/cgt.2017.15</mixed-citation></ref><ref id="scirp.81665-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Foster, T.H., Giesselman, B.R., Hu, R., Kenney, M.E. and Mitra, S. (2010) Intratumor Administration of the Photosensitizer Pc 4 Affords Photodynamic Therapy Efficacy and Selectivity at Short Drug-Light Intervals. Translational Oncology, 3, 135-141. https://doi.org/10.1593/tlo.09295</mixed-citation></ref><ref id="scirp.81665-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Mannino, S., Molinari, A., Sabatino, G., Ciafrè, S.A., Colonel, M., Maira, G., Anile, C., Arancia, G. and Mangiola, A. (2008) Intratumoral vs. Systemic Administration of Meta-Tetrahydroxyphenylchlorin for Photodynamic Therapy of Malignant Gliomas: Assessment of Uptake and Spatial Distribution in C6 Rat Glioma Model. International Journal of Immunopathology and Pharmacology, 21, 227-231. https://doi.org/10.1177/039463200802100126</mixed-citation></ref><ref id="scirp.81665-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Anatelli, F., Mroz, P., Liu, Q., Yang, C., Castano, A.P., Swietlik, E. and Hamblin, M.R. (2006) Macrophage-Targeted Photosensitizer Conjugate Delivered by Intratumoral Injection. Molecular Pharmaceutics, 3, 654-664. https://doi.org/10.1021/mp060024y</mixed-citation></ref><ref id="scirp.81665-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Goins, B., Phillips, W.T. and Bao, A. (2016) Strategies for Improving the Intratumoral Distribution of Liposomal Drugs in Cancer Therapy. Expert Opinion on Drug Delivery, 13, 873-889.</mixed-citation></ref></ref-list></back></article>